title: Effects of pharmacological entopeduncular manipulations on idiopathic dystonia in the dt(sz) mutant hamster.
abstract: The pathophysiology of idiopathic dystonias is still unknown, but it is regarded as a basal ganglia disorder. Previous experiments in the dt(sz) hamster, a model of primary paroxysmal dystonia, demonstrated reduced discharge rates and an abnormal pattern within the entopeduncular nucleus (EPN), a basal ganglia output structure. To clarify if this is based on abnormal gamma-aminobutyric acid(GABA)ergic or glutamatergic input, microinjections into the EPN were done in mutant hamsters in the present study. The GABA(A) receptor antagonists pentylenetetrazole and bicuculline exerted moderate antidystonic effects, while previous systemic administrations worsened dystonia in the dt(sz) mutant. GABA-potentiating drugs, i.e., the GABA(A) receptor agonist muscimol and the GABA transporter inhibitor 1,2,5,6-tetrahydro-1-[2-[[(diphenylmethylene)amino]oxy]ethyl]-3-pyridinecarboxy-lic acid (NNC-711), which are known to improve dystonia after systemic treatment in mutant hamsters, did not exert significant effects after EPN injections, but NNC-711 tended to increase the severity at the highest dose (2.5 ng bilateral). The NMDA receptor antagonist D(-)-2-amino-5-phosphopentanoic acid (AP-5) retarded the onset of a dystonic attack. However, this effect was not dose dependent and the AMPA receptor antagonist 2,3-dihydroxy-6-nitro-7-sulfamoylbenzol(f)quinoxaline (NBQX) alone or in combination with AP-5 and NNC-711, also failed to show any effects on dystonia. The present data do not provide clear evidence for an enhanced striatal GABAergic input or a reduced glutamatergic activation of the EPN via the subthalamic nucleus, i.e., more pronounced antidystonic effects of GABA(A) receptor antagonists and stronger prodystonic effects of GABAmimetics and glutamate receptor antagonists were expected. Nevertheless, previously found changes in entopeduncular activity probably play a critical pathophysiological role in dystonic hamsters.
authors.affiliation: Department of Veterinary Medicine, Institute of Pharmacology and Toxicology, Freie Universität Berlin, Koserstr. 20, 14195 Berlin, Germany. Hamann.Melanie@vetmed.fu-berlin.de
authors.forename: Melanie
authors.initials: M
authors.lastname: Hamann
authors.forename: Svenja E
authors.initials: SE
authors.lastname: Sander
authors.forename: Annette
authors.initials: A
authors.lastname: Kreil
authors.forename: Angelika
authors.initials: A
authors.lastname: Richter
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D006224:Cricetinae; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004421:Dystonia / Q000139:chemically induced / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D020392:Entopeduncular Nucleus / Q000187:drug effects* / Q000503:physiopathology*; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology*; D018682:GABA Agents / Q000494:pharmacology*; D008845:Microinjections / Q000379:methods; D009118:Muscimol / Q000494:pharmacology; D009557:Nipecotic Acids / Q000494:pharmacology; D010091:Oximes / Q000494:pharmacology; D010433:Pentylenetetrazole / Q000494:pharmacology; D011810:Quinoxalines / Q000494:pharmacology; D011930:Reaction Time / Q000187:drug effects; D012720:Severity of Illness Index; D013997:Time Factors; D014633:Valine / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: D018691:Excitatory Amino Acid Antagonists; D018682:GABA Agents; D009557:Nipecotic Acids; D010091:Oximes; D011810:Quinoxalines; C062865:2,3-dioxo-6-nitro-7-sulfamoylbenzo(f)quinoxaline; C078793:NNC 711; D009118:Muscimol; C056639:2-amino-5-phosphopentanoic acid; D014633:Valine; D010433:Pentylenetetrazole
references.citation: Prog Neurobiol. 1998 Dec;56(5):507-40
references.pmid: 9775402
references.citation: J Neurosci. 2008 Dec 17;28(51):13967-77
references.pmid: 19091985
references.citation: Exp Brain Res. 1994;102(2):244-58
references.pmid: 7705503
references.citation: Neurobiol Dis. 2010 May;38(2):288-98
references.pmid: 20138992
references.citation: Eur J Pharmacol. 2002 May 17;443(1-3):59-70
references.pmid: 12044793
references.citation: Mov Disord. 2006 Oct;21(10):1566-77
references.pmid: 16830313
references.citation: Eur J Pharmacol. 1993 Feb 9;231(2):287-91
references.pmid: 8384114
references.citation: Neuropathol Appl Neurobiol. 2006 Feb;32(1):74-82
references.pmid: 16409555
references.citation: J Neurosci. 2001 Jul 1;21(13):RC153
references.pmid: 11406638
references.citation: J Neuropathol Exp Neurol. 2005 Sep;64(9):776-81
references.pmid: 16141787
references.citation: Brain Res. 2004 May 15;1008(1):126-30
references.pmid: 15081391
references.citation: J Neurosci. 2009 Jun 17;29(24):7797-802
references.pmid: 19535591
references.citation: Eur J Pharmacol. 1992 Dec 2;224(2-3):189-98
references.pmid: 1468507
references.citation: Eur J Pharmacol. 2007 Jun 1;563(1-3):102-8
references.pmid: 17349621
references.citation: J Pharmacol Exp Ther. 2008 Aug;326(2):646-56
references.pmid: 18451317
references.citation: Brain Res. 1999 Mar 13;821(2):277-85
references.pmid: 10064814
references.citation: Eur J Pharmacol. 2005 Oct 3;521(1-3):95-8
references.pmid: 16183056
references.citation: Neurobiol Dis. 2009 Sep;35(3):399-405
references.pmid: 19501651
references.citation: Neurobiol Aging. 1994 Mar-Apr;15(2):259-60
references.pmid: 7838306
references.citation: J Neurophysiol. 2005 Jun;93(6):3165-76
references.pmid: 15703229
references.citation: Nat Rev Neurosci. 2008 Mar;9(3):222-34
references.pmid: 18285800
references.citation: Brain Res. 2007 May 30;1150:190-9
references.pmid: 17391652
references.citation: Ann Neurol. 1999 Jul;46(1):22-35
references.pmid: 10401777
references.citation: Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8
references.pmid: 18267265
references.citation: J Comp Neurol. 2000 Oct 23;426(3):366-77
references.pmid: 10992243
references.citation: Adv Neurol. 1998;78:1-10
references.pmid: 9750897
references.citation: Neurochem Res. 1996 Oct;21(10):1201-7
references.pmid: 8923481
references.citation: J Neurosci. 2000 Sep 15;20(18):7052-8
references.pmid: 10995851
references.citation: J Neurosci Res. 2009 Feb 15;87(3):776-83
references.pmid: 18831004
references.citation: Clin Neurophysiol. 2004 Jun;115(6):1239-48
references.pmid: 15134690
references.citation: Eur J Pharmacol. 2002 May 3;442(1-2):81-92
references.pmid: 12020685
references.citation: J Neurosci. 2002 Aug 15;22(16):7244-53
references.pmid: 12177219
references.citation: Prog Neurobiol. 1998 Apr;54(6):633-77
references.pmid: 9560845
references.citation: Neurotherapeutics. 2008 Apr;5(2):281-93
references.pmid: 18394570
references.citation: Curr Med Chem. 2000 Oct;7(10):1063-79
references.pmid: 10911018
references.citation: Prog Brain Res. 2007;160:287-312
references.pmid: 17499121
references.citation: Pharmacology. 2007;80(2-3):127-33
references.pmid: 17534122
references.citation: Acta Neurochir Suppl. 2007;97(Pt 2):191-9
references.pmid: 17691304
references.citation: NeuroRx. 2005 Jul;2(3):504-12
references.pmid: 16389314
references.citation: J Neurophysiol. 2007 Apr;97(4):2627-41
references.pmid: 17215512
references.citation: Neuroreport. 2004 Jun 28;15(9):1391-3
references.pmid: 15194859